Business Context and Reporting Period
Company: Tango Therapeutics, Inc. (TNGX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2026
Reporting Period: Quarter ended December 31, 2025
This filing serves as a notification that the Company issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2025. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific financial data. The following metrics are not present in this filing text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Investors must refer to the attached press release (Exhibit 99.1) for specific numerical values.
Material Changes
The filing text does not disclose specific material changes, variances, or comparative data versus the prior period. It only confirms the issuance of a report containing such information.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing management commentary on the quarter's results but does not reproduce the commentary itself.
Guidance and Outlook: No forward-looking guidance or outlook is included in the text of this Form 8-K.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release) for actual financial figures, as they are not embedded in the 8-K text.
- Verify the specific revenue, net loss, and cash burn rate for the quarter ended December 31, 2025, in the press release.
- Check for any updated clinical trial milestones or partnership announcements mentioned in the press release.
- Confirm the Company's cash runway and liquidity position as stated in the press release.